Abeona Therapeutics Inc.
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases.
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend purchasing Abeona Therapeutics’ stock, expecting its price to rise significantly.
Financial Health
Abeona Therapeutics is showing good cash flow and a steady book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ABEO
Orphan Drug Moats: Leaders In Rare Disease
The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.
Published: August 20, 2025
Explore BasketGene Therapy's Regulatory Tailwind
Sarepta Therapeutics' stock surged after the FDA re-approved its gene therapy for muscular dystrophy, signaling a positive turn for the industry. This development creates a potential tailwind for other biotech companies specializing in novel treatments for rare genetic diseases.
Published: July 30, 2025
Explore BasketPioneers In Rare Disease Therapy
The FDA's approval of PTC Therapeutics' drug for the rare disorder PKU marks a significant advancement in metabolic disease treatment. This event creates an investment opportunity by highlighting the growth potential of other biopharmaceutical companies specializing in therapies for rare genetic conditions.
Published: July 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Milestones Ahead
Progress in trials or regulatory news can sharply re-rate the stock, though clinical setbacks are common and can quickly reverse gains.
Small-cap Volatility
With a market cap near $280M, Abeona can show large price swings; potential returns come with higher risk and financing sensitivity.
Rare Disease Focus
Targeting rare genetic disorders means high unmet medical need and potential partner interest, but patient populations are small and outcomes uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
